Retatrutide Guide: Triple-Agonist Weight Loss for Veterans

Retatrutide: What Veterans Need to Know About the Triple-Agonist Weight Loss Drug

Retatrutide is an investigational triple-agonist drug developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors. In Phase 3 trials, it produced up to 28.3% weight loss at 80 weeks. It is not FDA-approved and is legally available only through clinical trials. Veterans cannot currently access it through VA or TRICARE.

What Is Retatrutide?

Retatrutide is an investigational once-weekly injectable medication developed by Eli Lilly for obesity, type 2 diabetes, and related metabolic conditions. It is a first-in-class triple hormone receptor agonist, meaning it activates three receptors simultaneously: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon.

The drug is also known by its development code, LY3437943. In online communities, it is sometimes called “reta” or “triple-G”. Retatrutide is a single molecule with 39 amino acids and a molecular weight of approximately 4,731 Da.

Retatrutide is not the same as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro). Semaglutide targets only GLP-1. Tirzepatide targets GLP-1 and GIP. Retatrutide adds a third target — glucagon — which may contribute to its greater weight loss effects in clinical trials.

How Retatrutide Works: Triple-Agonist Mechanism

Retatrutide activates three hormone receptors that regulate appetite, blood sugar, and energy metabolism. This triple mechanism is what distinguishes it from currently approved weight loss medications.

GLP-1 Receptor Activation

GLP-1 (glucagon-like peptide-1) slows stomach emptying, reduces appetite, and improves blood sugar control. This is the same mechanism used by semaglutide and liraglutide. GLP-1 activation is the foundation of most modern weight loss drugs.

GIP Receptor Activation

GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion and may improve how the body processes fat. Tirzepatide also targets GIP, and its dual mechanism is one reason it outperforms semaglutide in head-to-head comparisons.

Glucagon Receptor Activation

Glucagon receptor activation increases energy expenditure and promotes fat burning. This third mechanism is unique to retatrutide among late-stage weight loss drugs. The addition of glucagon agonism is believed to explain the additional weight loss seen in clinical trials compared to dual agonists.

Clinical Trial Results: The TRIUMPH Program

Retatrutide has been studied in five Phase 3 trials under the TRIUMPH program. All five trials met their primary endpoints, showing substantial weight loss across multiple patient populations.

TRIUMPH-1: Obesity Without Diabetes

In TRIUMPH-1, 2,339 adults with obesity (without diabetes) received retatrutide at 4 mg, 9 mg, or 12 mg, or placebo for 80 weeks. The results were published in the New England Journal of Medicine in September 2026.

Among participants on the 12 mg dose, 65.3% achieved a BMI below 30 (no longer meeting obesity criteria), and 45.3% lost at least 30% of their body weight — a level historically associated with bariatric surgery.

The trial also included nested studies for knee osteoarthritis and obstructive sleep apnea. Retatrutide reduced knee osteoarthritis pain by up to 4.3 points (73.1%) and reduced sleep apnea severity by up to 36.1 events per hour (60.6%).

TRIUMPH-2: Type 2 Diabetes and Obesity

In TRIUMPH-2, adults with type 2 diabetes and obesity received retatrutide at 4 mg, 9 mg, or 12 mg. At 80 weeks, participants lost an average of 12.7%, 19.1%, and 20.8% of their body weight, respectively, alongside A1C reductions of up to 1.6%.

TRIUMPH-3: Severe Obesity and Cardiovascular Disease

In TRIUMPH-3, adults with severe obesity and established cardiovascular disease (with or without type 2 diabetes) received retatrutide at 9 mg or 12 mg. At 80 weeks, participants lost an average of 22.0% and 22.6% of their body weight, respectively.

TRANSCEND-T2D-1: Type 2 Diabetes

In the TRANSCEND-T2D-1 trial, participants with type 2 diabetes achieved A1C reductions of up to 2.0% and weight loss of up to 16.8% at 40 weeks. Up to 90% of participants achieved an A1C below 7.0%.

How Retatrutide Compares to Semaglutide and Tirzepatide

Retatrutide produces greater average weight loss than any currently approved weight loss medication in clinical trials. A network meta-analysis published in BMJ Medicine compared GLP-1-based drugs and found that retatrutide achieved the greatest average weight reduction at −22.10%, followed by tirzepatide at −19.28% and CagriSema at −17.32%.

The comparison data comes from separate trials, not head-to-head studies. Direct head-to-head trials between retatrutide and approved medications have not been completed.

Is Retatrutide FDA-Approved?

No. Retatrutide is not approved by the FDA or any regulatory agency worldwide as of October 2026. It remains strictly investigational and is legally available only through Eli Lilly’s authorized clinical trials.

Eli Lilly has announced plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. If approved, the earliest estimated market launch would be early 2028.

Important: Because retatrutide is not approved, it has no brand name, no NDC code, no list price, and no insurance coverage pathway. Anything sold under the name “retatrutide” outside of clinical trials is unapproved, unverified, and potentially dangerous.

Can Retatrutide Be Compounded?

No. Retatrutide cannot be legally compounded under federal law. The FDA has stated that retatrutide cannot be used in compounding because it is not an approved drug and is not on the FDA’s compounding list.

Eli Lilly has filed multiple lawsuits against compounding pharmacies, medical spas, and online sellers marketing retatrutide products. The company has reported over 14,000 websites and product listings marketing retatrutide across more than 100 countries.

There is an ongoing legal dispute about whether retatrutide should be classified as a biologic or a drug under the 40-amino-acid threshold. However, regardless of how that case resolves, the FDA has been clear that retatrutide cannot be legally compounded today.

Retatrutide Availability for Veterans: What You Need to Know

Veterans cannot currently access retatrutide through the VA, TRICARE, or CHAMPVA. The drug has no NDC code, no formulary placement, and no legal pathway for prescription or dispensing outside of clinical trials.

VA Coverage

The VA does not cover retatrutide. The VA covers certain FDA-approved GLP-1 medications for weight management, but only for veterans who meet specific criteria. Wegovy (semaglutide) and Zepbound (tirzepatide) are available non-formulary with prior authorization for veterans with a BMI of 30 or higher, or a BMI of 27–29.9 with at least one weight-related condition.

CHAMPVA, which covers dependents of 100% permanently and totally disabled veterans, does not cover GLP-1 medications for weight loss at all. CHAMPVA covers GLP-1 drugs only for FDA-approved indications like type 2 diabetes.

TRICARE Coverage

TRICARE does not cover retatrutide. As of August 31, 2025, TRICARE no longer covers weight loss drugs for beneficiaries when obesity is the primary diagnosis, except for those enrolled in TRICARE Prime or TRICARE Select. TRICARE For Life beneficiaries lost weight loss drug coverage entirely as of that date.

TRICARE currently covers semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management for eligible beneficiaries with prior authorization.

What Veterans Can Do Now

• Enroll in a clinical trial: The only legal way to access retatrutide today is through an authorized Eli Lilly clinical trial. Veterans can search ClinicalTrials.gov for recruiting studies.

• Ask about approved alternatives: Veterans should talk to their VA provider about semaglutide (Wegovy) or tirzepatide (Zepbound), which are FDA-approved and may be covered by VA or TRICARE with prior authorization.

• Join the MOVE! program: The VA’s MOVE! Weight Management Program is available to all enrolled veterans with a BMI of 25 or higher. The program provides lifestyle intervention and can be a prerequisite for weight loss medication or bariatric surgery.

Retatrutide Clinical Trials: How Veterans Can Enroll

Enrolling in an authorized clinical trial is the only legal way to access retatrutide before FDA approval. Eli Lilly’s TRIUMPH program has enrolled over 5,800 participants across multiple trials.

Eligibility Criteria

Typical eligibility criteria for retatrutide trials include:

• BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related condition (such as hypertension, type 2 diabetes, sleep apnea, or dyslipidemia).

• Age 18 or older.

• No history of severe gastrointestinal disease.

• Willingness to participate in a long-term study (up to 104 weeks).

How to Find a Trial

1. Visit ClinicalTrials.gov: Search for “retatrutide” or “LY3437943.”

2. Filter by status: Look for studies that are “Recruiting” or “Active, not recruiting.”

3. Contact the study site: Each listing includes contact information for the research team.

4. Verify legitimacy: Only Eli Lilly-sponsored trials are authorized. Be wary of any program that charges for participation.

Veterans who enroll in clinical trials receive the medication at no cost and are monitored by medical professionals. However, participants may receive placebo rather than the active drug.

Safety and Side Effects

The most common side effects of retatrutide in clinical trials were gastrointestinal, including nausea, diarrhea, and vomiting. These effects occurred primarily during dose escalation and were generally mild to moderate.

Common Side Effects

Discontinuation rates due to adverse events were 5.1% for the 12 mg dose compared to 0.0% for placebo.

Serious Warnings

• Pancreatitis: Acute pancreatitis has been reported with GLP-1 receptor agonists. Stop use and seek medical attention if severe abdominal pain occurs.

• Hypersensitivity reactions: Anaphylaxis and other serious allergic reactions have been reported. Seek immediate medical attention if rash, swelling, or difficulty breathing occurs.

• Ketoacidosis: A case of severe non-diabetic ketoacidosis was reported with supratherapeutic compounded retatrutide use.

Counterfeit and Black Market Risks

Retatrutide sold outside of clinical trials is unregulated and unverified. The U.S. poison control system reported a 265% increase in cases attributed to drugs sold as retatrutide in the first four months of 2026. Serious adverse events, including uncontrollable vomiting requiring hospitalization, have been reported with counterfeit retatrutide products.

Retatrutide Cost and Projected Pricing

There is no official price for retatrutide because it is not approved or commercially available. Any price quoted online is for a gray-market research vial, not a finished pharmaceutical product.

Current Gray-Market Pricing

Source: PeptidesExplorer

These products are not manufactured under pharmaceutical-grade oversight. Their purity, potency, and sterility are unverified. Veterans should not purchase or use these products.

Projected Post-Approval Pricing

If approved, retatrutide is expected to be priced similarly to tirzepatide (Zepbound), which has a list price of approximately $1,060 per month. Analysts project a list price of $1,100–$1,500 per month for retatrutide. Insurance coverage and manufacturer savings programs would be expected to reduce out-of-pocket costs for eligible patients.

Common Mistakes Veterans Make with Retatrutide

1. Buying from unregulated online sellers: Retatrutide sold outside of clinical trials is illegal, unverified, and potentially dangerous. Poison control cases have increased sharply.

2. Assuming VA or TRICARE will cover it: Retatrutide has no NDC code and no formulary placement. It cannot be prescribed or covered until FDA approval.

3. Confusing retatrutide with tirzepatide or semaglutide: These are different drugs with different mechanisms. Only tirzepatide and semaglutide are FDA-approved.

4. Ignoring approved alternatives: Veterans who qualify for weight loss medication should ask their VA provider about Wegovy or Zepbound, which are covered with prior authorization.

5. Not exploring clinical trial enrollment: The only legal way to access retatrutide today is through a clinical trial. Veterans should check ClinicalTrials.gov.

6. Skipping the MOVE! program: MOVE! is the VA’s foundational weight management program and is often required before medication or surgery is considered.

Latest Updates and Regulatory Timeline

• September 2026: TRIUMPH-1 results published in the New England Journal of Medicine.

• July 2026: Eli Lilly announced plans to submit a Biologics License Application (BLA) in Q1 2027.

• August 2026: Eli Lilly filed six new lawsuits against U.S. businesses selling illegal retatrutide products.

• September 2026: Seventh Circuit heard oral arguments on whether retatrutide should be classified as a biologic or a drug.

• Projected timeline: FDA submission in Q1 2027, potential approval in late 2027 or early 2028.

Common Questions

1. What is retatrutide?
Retatrutide is an investigational once-weekly injectable drug developed by Eli Lilly for obesity and type 2 diabetes. It is a triple agonist that targets GLP-1, GIP, and glucagon receptors. It is not FDA-approved and is available only through clinical trials.

2. Is retatrutide approved by the FDA?
No. Retatrutide is not approved by the FDA or any regulatory agency worldwide. Eli Lilly plans to submit a Biologics License Application in the first quarter of 2027, with a possible market launch in early 2028.

3. Can veterans get retatrutide through the VA?
No. The VA does not cover retatrutide. The drug has no NDC code and cannot be prescribed or dispensed. Veterans can only access retatrutide through an authorized clinical trial.

4. Does TRICARE cover retatrutide?
No. TRICARE does not cover retatrutide or any weight loss drug when obesity is the primary diagnosis, except for beneficiaries enrolled in TRICARE Prime or TRICARE Select. Retatrutide is not on any TRICARE formulary.

5. Can retatrutide be compounded?
No. The FDA has stated that retatrutide cannot be used in compounding under federal law. It is not an approved drug and is not on the FDA’s compounding list. Eli Lilly has sued multiple compounding pharmacies for selling illegal retatrutide.

6. How much weight loss does retatrutide cause?
In the TRIUMPH-1 trial, participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks and 30.3% at 104 weeks. This is greater than any currently approved weight loss medication.

7. What are the side effects of retatrutide?
The most common side effects are nausea, diarrhea, and vomiting, primarily during dose escalation. Serious risks include pancreatitis, hypersensitivity reactions, and ketoacidosis. Discontinuation rates due to side effects were 5.1% at the highest dose.

8. How can I enroll in a retatrutide clinical trial?
Visit ClinicalTrials.gov and search for “retatrutide” or “LY3437943.” Filter for recruiting studies. Eligibility typically requires a BMI of 30 or higher, or a BMI of 27 or higher with a weight-related condition.

9. Is retatrutide better than Ozempic or Zepbound?
In separate clinical trials, retatrutide produced greater average weight loss than semaglutide (Ozempic/Wegovy) and tirzepatide (Zepbound). However, no head-to-head trials have been completed. Tirzepatide and semaglutide are FDA-approved; retatrutide is not.

10. What should veterans do if they want retatrutide now?
Veterans should talk to their VA provider about FDA-approved alternatives like Wegovy or Zepbound. They can also enroll in the MOVE! Weight Management Program and search ClinicalTrials.gov for retatrutide trial opportunities.

11. Is retatrutide safe?
In clinical trials, retatrutide’s safety profile was consistent with other GLP-1-based therapies. However, it is not FDA-approved, and long-term safety data beyond 104 weeks is not yet available. Black market products are unverified and dangerous.

12. When will retatrutide be available?
Eli Lilly plans to submit a Biologics License Application to the FDA in Q1 2027. If approved, the earliest estimated market launch is early 2028. VA and TRICARE coverage decisions would follow FDA approval.

Key Takeaways

• Retatrutide is an investigational triple-agonist drug targeting GLP-1, GIP, and glucagon receptors.

• It produced up to 28.3% weight loss at 80 weeks and 30.3% at 104 weeks in Phase 3 trials — greater than any approved weight loss medication.

• It is not FDA-approved and is legally available only through Eli Lilly’s clinical trials.

• Veterans cannot access retatrutide through VA, TRICARE, or CHAMPVA.

• Retatrutide cannot be legally compounded under federal law.

• The only legal way to access retatrutide today is through a clinical trial.

• Black market retatrutide is unverified, illegal, and linked to serious adverse events.

• FDA submission is planned for Q1 2027; market launch is estimated for early 2028.

• Veterans should ask their VA provider about approved alternatives like Wegovy and Zepbound.

• The VA’s MOVE! program is available to all enrolled veterans with a BMI of 25 or higher.

Official Resources

• ClinicalTrials.gov: clinicaltrials.gov — Search for retatrutide trials

• U.S. Department of Veterans Affairs: va.gov | 1-800-827-1000

• VA MOVE! Weight Management Program: va.gov/MOVE

• TRICARE: tricare.mil

• CHAMPVA: va.gov/CHAMPVA

• U.S. Food and Drug Administration: fda.gov

• USA.gov Veterans Benefits: usa.gov/veterans-benefits

• Eli Lilly Retatrutide Information: lilly.com

• Medicare: medicare.gov | 1-800-633-4227

• Social Security Administration: ssa.gov | 1-800-772-1213